solved more precisely and rationally than by the use of opiates. A close watch should be kept upon bladder function.
Mr T M Coltart (Guy's Hospital, London) wanted to know the medico-legal position of an obstetrician giving an epidural himself when there were trained anesthetists within the hospital. He asked whether, when complications arose, the obstetrician would be considered liable.
The President (Dr A H Galley, King's College Hospital, London) felt that, since obstetricians could in any case give local analgesia, they were medico-legally covered.
Dr R A Green (Royal Free Hospital, London) thought the speakers had established convincingly the value of epidural analgesia in obstetrics. It remained for the rest to campaign for the establishment of consultant sessions in obstetric anisthesia.
Mr Kenneth Cooper stated that the Central Midwives Board had agreed that midwives could 'top up' epidural anwesthetics subject to certain conditions and provided they had received instruction in the method. They were legally covered to do this. Dr A P Rubin (Charing Cross Hospital, London) said that a total spinal was one of the most feared and dangerous complications of obstetric epidurals. This hazard could be reduced, and money saved, if the use of bacterial filters was abandoned. They prevented satisfactory aspiration prior to injection, added considerable resistance and frequently leaked. Infection could be prevented simply by using Tuohy-Borst adaptors with caps, and a sterile technique during re-injection. Dr J M B Burn considered the introduction of bacterial filters to be one ofthe most important factors in making prolonged epidural analgesia a practical proposition. Puncture of the dura by epidural catheters at the time of 'top up' must be excessively rare and the hazard of a total spinal could be avoided by the use of a test dose injection.
Dr A G Doughty said that although speakers had rightly referred to the possibility of complications following epidural analgesia, the complications of not providing an epidural service should not be ignored. The memory of a particularly painful experience in labour might result in voluntary 'one child' infertility or at least in undue apprehension of subsequent childbirth. Efforts to alleviate severe pain with large doses of narcotics might cause serious neonatal depression. CQsa-rean section might even be performed for what would otherwise be remediable maternal distress. Mothers might be needlessly exposed to the hazards of general anmsthesia for a difficult vaginal delivery. These were all considerations which should be balanced against the preoccupation with complications, the majority of which should be avoidable by proper attention to the details of technique and to the care of the patient.
The following paper was also read: McAuliff, Luduena & Brown 1967 , Lands, Luduena & Buzzo 1967 have proposed a subdivision of ,B-adrenoceptors into two groups designated P, and P2. Stimulation of heart muscle is mediated by PI-receptors and relaxation of bronchial, arterial and uterine muscle by P2receptors. Skeletal muscle also contains P2receptors. The Lands classification has gained more general acceptance since the discovery of salbutamol and other highly selective ,2-stimulants (Brittain et al. 1970 ). This paper describes some pharmacological properties of the recently synthesized ,B-stimulants.
The starting point for the recent P-stimulants was isoprenaline. This substance is a potent stimulant of all P-adrenoceptors and has little effect on a-adrenoceptors. For many years isoprenaline dominated the sympathomimetic treatment of asthma. Its prime advantage is its speed of action: after inhalation intense bronchodilatation occurs within seconds. However, isoprenaline has serious disadvantages because its action is brief and nonselective and the drug is inactive by mouth. Many attempts have been made to im- ,-receptors in different tissues. More recent attempts to improve isoprenaline have been aimed at replacing the catechol function by groupings which retain some of its obvious chemical properties such as a chelating activity or its ability to form hydrogen bonds. This approach has led to the discovery of several series of active P-stimulants, the best known of which are the saligenin derivative salbutamol (Cullum et al. 1969) , the resorcinal derivatives, orciprenaline (Engelhardt et al. 1961 ) and terbutaline (Bergmann et al. 1969 ) and the tetrahydroisoquinoline derivative trimetoquinol (Iwasawa & Kiyomoto 1967) . The main object of the experiments described was to compare the pharmacological properties of salbutamol, orciprenaline, terbutaline and trimetoquinol with those of isoprenaline.
Effects of P-stimulants in the guinea-pig: The results obtained are summarized in Table 1 . Apart from differences in potency isoprenaline and orciprenaline are essentially alike in their effects on bronchial and cardiac muscle in the whole animal. In contrast, salbutamol, terbutaline and trimetoquinol are full agonists on tracheo-bronchial muscle but are partial agonists and much weaker in action than isoprenaline on cardiac muscle. At equi-effective doses all the newer P-stimulants were longer acting than isoprenaline because they are not readily taken up into cells, or degraded by catechol-O-methyl transferase (COMT) or sulphatase enzymes. By aerosol, and by mouth, salbutamol was particularly active as a bronchodilator agent in the guinea-pig.
Effects of P-stimulants in the cat: The results of investigations carried out in the anzesthetized cat are summarized in Table 2 . All the ,-stimulants reduced resting pulmonary resistance but there was no obvious separation of this effect from that on soleus muscle. However, salbutamol and terbutaline had distinctly less effect than the other drugs in increasing heart rate. Trimetoquinol was not a selective P-stimulant in the cat.
Effects of salbutamol in the anasthetized dog: In the anesthetized dog isoprenaline 0.01-1 ,sg/kg, or salbutamol 0.1-10 /ag/kg intravenously, lowered arterial blood pressure, increased cardiac output and increased heart rate. Salbutamol was less potent than isoprenaline on all these parameters and its low positive chronotropic activity was particularly marked (Daly et al. 1971 ). Both Section ofAnesthetics 761 salbutamol and isoprenaline increased cardiac output. With isoprenaline this was achieved by an increase in heart rate. The increased cardiac output after salbutamol resulted from increased stroke volume without marked chronotropy. It was almost certainly P2 in origin because it depended on increased venous return caused by dilatation of peripheral blood vessels. Similar cardiovascular effects in man would make salbutamol a possibly useful drug for the treatment of cardiogenic shock.
Discuission
The results show that isoprenaline does not differentiate between P-receptors in different tissues and the selectivity of orciprenaline is small. In contrast, salbutamol is clearly more active on bronchial smooth muscle than on cardiac muscle; it is also longer acting than isoprenaline. Terbutaline is rather like salbutamol but is less active. Trimetoquinol is not obviously selective in its in vivo actions. Lands and his colleagues were the first to propose a P1, P2 classification of P-adrenoceptors but it is interesting to see that evidence for this classification was already present in the literature, particularly in the work of Furchgott (1967) who showed that the sensitivity of tracheal muscle and heart muscle to the natural transmitters, noradrenaline and adrenaline, were significantly different. The results given in this paper are even better evidence for the Lands proposals. P1and P2-receptors must obviously be chemically different. It is most likely that the P2-receptor allows an additional ordering interaction with the N-methyl substituent of adrenaline. The interactions of the receptors with selective synthetic agonists such as salbutamol must be more varied and could well involve exo-receptor sites. Those interactions at P2 sites must be ordering and thus cause agonistic responses; any interactions which occur at P1 sites must be disordering and lead to partial agonistic or blocking effects. The concept of the adrenergic receptor was proposed by Langley (1905) and substantiated by Dale (1906) . Dale showed that adrenaline contracted vascular, cardiac, splenic and uterine muscle, but relaxed biliary and intestinal smooth muscle. In animals previously given the alkaloid ergot, the action of adrenaline was reversed in that it relaxed splenic, uterine and vascular smooth muscle, but its action on biliary and intestinal muscle was unchanged. The stimulant actions of adrenaline on the heart, piloerector muscles and dilator iridis were prevented.
In current terminology, these results would be interpreted as showing that adrenaline has astimulant actions on splenic and vascular muscle which is converted to a P inhibitory response in the presence of the a blocking agent, ergot. The reversal of adrenaline effects is due to its action on P-receptors, which can only be observed in the presence of a-receptor blockade. Ergot has predominantly a-blocking actions and, in high doses, some P-receptor blocking action on the heart. The first specific P-receptor blocking drug to be discovered was dichloroisoprenaline (DCI) (Powell & Slater 1958) . This compound was soon followed by pronethalol (Black & Stevenson 1962) , and propranolol (Black et al. 1965) . Currently, more than 20 pharmaceutical companies are synthesizing and testing a wide variety of compounds for P-adrenergic blocking activity. A P-blocking drug may be defined as a competitive specific antagonist at the P-receptor (Barrett & Fitzgerald 1968) . A competitive antagonist may be defined as one which moves the dose-response curve for agonist/antagonist interaction to the right without changing its slope. Specific antagonism implies blockade of only the adrenoceptive site. Thus Dale (1906) showed that ergot, whilst blocking the action of adrenaline on vascular muscle, did not prevent vasoconstriction by pituitrin. Similarly, propranolol and practolol block the positive inotropic actions of the specific P-stimulant isoprenaline, but do not block the actions of acetylstrophanthidin, calcium or glucagon, nor do they antagonize the actions of histamine or acetylcholine.
Once the first P-receptor blocking drugs had been discovered, research concentrated on finding compounds that were not only specific but also more potent and more selective. Selectivity, as opposed to specificity, of P-receptor blockade
